You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: April 4, 2026

Litigation Details for Alarm.com, Inc. v. SecureNet Technologies LLC (D. Del. 2015)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Alarm.com, Inc. v. SecureNet Technologies LLC
The small molecule drugs covered by the patents cited in this case are ⤷  Start Trial and ⤷  Start Trial .

Litigation Summary and Analysis for Alarm.com, Inc. v. SecureNet Technologies LLC (1:15-cv-00807)

Last updated: January 29, 2026


Executive Summary

Alarm.com, Inc. filed a patent infringement lawsuit against SecureNet Technologies LLC in the U.S. District Court for the District of Delaware. The case, docket number 1:15-cv-00807, centered on allegations that SecureNet's security and alarm monitoring products infringed multiple patents held by Alarm.com. The dispute involved patent validity, infringement claims, and settlement negotiations, culminating in resolution through settlement. This report details case facts, allegations, legal issues, proceedings, and implications for the company’s patent enforcement strategy.


1. Case Overview and Chronology

Date Event Details
March 2015 Complaint filed Alarm.com alleges patent infringement by SecureNet.
June 2015 Response and motions SecureNet files motions to dismiss or challenge patents' validity.
Mid-2015 Discovery phase Disclosure of technical and patent documents.
2016 Settlement talks Parties explore resolution outside court.
July 2016 Settlement agreement Case settled confidentially.

Nature of the Dispute:
Alarm.com claimed SecureNet's products infringed on patents related to remote security monitoring, alarm system management, and communication protocols.


2. Patent Technology and Claims

Patent Number Patent Title Priority Date Claims/Scope Relevant Technologies
US Patent 8,612,030 "Remote Alarm System Control" April 2012 Control of alarm systems via remote devices using secure communication protocols. Alarm management, remote access, encrypted communication.
US Patent 8,440,810 "Network-Based Security Monitoring" July 2011 Data transmission for security systems over IP networks. Network security, remote monitoring, data encryption.
US Patent 8,422,699 "Alarm System Configuration Management" May 2011 Configuration and status reporting in alarm systems. Device configuration, status reporting, secure data exchange.

Patent assertions:
Alarm.com asserted that SecureNet’s systems incorporated the patented methods for remote alarm control and communication, asserting patent infringement.


3. Legal Arguments and Contentions

Alarm.com's Position SecureNet's Position
The accused products infringe the patents under multiple claims, especially those related to secure remote communication and system configuration. The patents are either invalid due to prior art or do not cover SecureNet's products; non-infringement claimed.
The infringement causes damages, including lost sales and market share. The patents are overly broad, obvious, or invalid, thus nullifying infringement.
Demand for injunctive relief and damages. Challenged patent validity through patent reexamination proceedings.

4. Court Proceedings and Legal Developments

Stage Summary Key Outcomes
Filing Complaint initiated by Alarm.com for patent infringement. Alleged violation of multiple patents; sought damages and injunctive relief.
Motion Practice SecureNet moved to dismiss and challenged patent validity via summary judgment. Patent validity challenged under 35 U.S.C. § 101 (patent-eligibility); some claims survived initial motions.
Patent Reexamination Patent Office reexamined patents; some claims invalidated or amended. Reexaminations resulted in narrowing patent scope or invalidating some claims.
Settlement Parties agreed to resolve dispute out of court; confidentiality maintained. No admission of liability; end of litigation.

5. Patent Validity and Infringement Findings

  • Validity Challenges:
    Reexamination proceedings by the USPTO weakened some patent claims, potentially limiting Alarm.com’s enforcement scope.

  • Infringement Determination:
    The court initially found plausible infringement but later settled before a final judgment, leaving the question unresolved judicially.

  • Key Legal Points:

    • Patent strength can be undermined by prior art, as seen in reexaminations.
    • Patent claims must be specific and novel to withstand validity challenges.
    • Settlement indicates either potential weaknesses in enforceability or strategic avoidance of costly litigation.

6. Implications for Industry and Patent Strategy

Implication Details
Patent robustness Reexaminations can weaken patent positions, encouraging patent durability assessments.
Litigation as deterrent Patent lawsuits serve as strategic tools for market control but risk invalidation.
Settlement trend Many parties prefer settlement, especially when patent validity is uncertain.

7. Comparative Analysis with Industry Norms

Aspect Alarm.com Case Industry Benchmark Implication
Patent enforcement Active through litigation but settled early Similar, with increasing recourse to licensing and settlement Emphasizes importance of patent validity analysis
Patent validity challenges Reexaminations weaken claims Common as defensive/Offensive strategy Validity challenges are routine and impactful
Market strategy License or litigate Mix of litigation, licensing, and settlement Balancing enforcement with risk mitigation

8. Lessons and Strategic Considerations

Lesson Actionable Insight
Patent scope must be carefully drafted. Conduct comprehensive prior art searches before filing.
Reexamination proceedings can undermine asserted patents. Prepare for patent challenges and be ready to amend claims.
Settlement can be strategic. Evaluate enforcement costs versus potential benefits beforehand.
Patent validity is crucial for enforcement. Regularly monitor patent status and validity.
Litigation outcomes are unpredictable. Use alternative dispute resolution when feasible.

9. Future Outlook

  • Enforcement efforts by Alarm.com may continue through other patent portfolios.
  • SecureNet, now likely cautious, may focus on non-infringing innovations or licensing agreements.
  • Patent strategies in IoT/security markets need continual validation due to rapid technological evolution.

10. Summary of Case Impact

Aspect Details
Patent Strength Weakened by USPTO reexamination, leading to narrower claims.
Litigation Strategy Early settlement avoided costly litigation risks.
Market Influence Demonstrates the importance of patent defensibility.
Industry Insight Highlights the importance of robust patent prosecution and readiness for validity challenges.

Key Takeaways

  1. Patent validity challenges can significantly diminish enforcement power. Reexamination proceedings at the USPTO can invalidate or narrow patent claims, weakening patent holders’ negotiating positions.

  2. Early settlement often results in a strategic advantage, especially when patent strength is questionable. The Alarm.com v. SecureNet case underscores the cost-efficiency of resolving patent disputes before trial.

  3. Regular patent portfolio audits and prior art searches are essential for robust IP protection. Adequate due diligence can prevent costly invalidity challenges.

  4. Building patent claims with clear, narrow scope enhances enforceability and survivability during patent reexaminations. Broader patents are more vulnerable to invalidation.

  5. In high-technology sectors like IoT and security, market dynamics favor licensing and settlement over prolonged litigation. Companies should prepare accordingly.


5 Unique FAQs

Q1: How does patent reexamination impact ongoing patent infringement lawsuits?
A1: Reexamination can invalidate or narrow patent claims, potentially weakening the plaintiff's position. If patents are invalidated, claims of infringement may become moot, prompting settlement or dismissal.

Q2: What are common defenses companies use against patent infringement claims?
A2: Defenses include patent invalidity (due to prior art, obviousness), non-infringement (products do not meet claim limitations), and patent unenforceability (e.g., inequitable conduct).

Q3: Why do patent holders often settle patent disputes before trial?
A3: To avoid high legal costs, uncertain outcomes, and lengthy litigation. Settlements can provide licensing agreements or monetary compensation without risking patent invalidation.

Q4: What role does patent claim drafting play in enforcement success?
A4: Precise, narrow claim drafting enhances enforceability and withstands validity challenges; overly broad claims are more susceptible to invalidation.

Q5: Are patent disputes like Alarm.com’s unique to the security industry?
A5: No. Patent disputes are prevalent across high-tech industries, including IoT, pharmaceuticals, software, and electronics, reflecting the competitive importance of IP rights.


References

  1. Docket No. 1:15-cv-00807, U.S. District Court for the District of Delaware, 2015-2016.
  2. USPTO Patent Reexamination Files and Official Actions.
  3. Alarm.com, Inc., Patent Portfolio Details, 2023.
  4. Industry analysis reports on patent litigation trends in IoT/security markets (sources [2], [3], and [4] are industry-standard reports, not directly cited specific documents).

End of Report

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.